Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador
- 1 January 1994
- Vol. 12 (4) , 337-342
- https://doi.org/10.1016/0264-410x(94)90098-1
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in ColombiaThe Lancet, 1993
- Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 yearsVaccine, 1992
- In human malaria protective antibodies are directed mainly against the Lys‐Glu ion pair within the Lys‐Glu‐Lys motif of the synthetic vaccine SPf 66Parasite Immunology, 1992
- A specific T‐cell receptor genotype preference in the immune response to a synthetic Plasmodium falciparum malaria vaccineParasite Immunology, 1992
- Protection against malaria by vaccination with sporozoite surface protein 2 plus CS proteinScience, 1991
- Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malariaClinical and Experimental Immunology, 1991
- Involvement of T cells in malaria immunity: implications for vaccine developmentVaccine, 1989
- A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malariaNature, 1988
- Induction of protective immunity against experimental infection with malaria using synthetic peptidesNature, 1987
- Solid Phase Peptide Synthesis. I. The Synthesis of a TetrapeptideJournal of the American Chemical Society, 1963